VTC Welcomes RICC Leadership Team to Nashville for in-person meeting
November 27, 2024
The RePORT International leadership team gathered in Nashville, Tennessee from 4-5 November 2024 for an in-person meeting. The group reviewed the RICC "Report Card" which assessed the progress made on the consortium's strategic goals for the past year, identified areas for improvement, and discussed big picture goals going forward.
VUMC investigators attend RePORT-International Annual Meeting
September 16, 2024
Dr. Dooley’s TB research receives MERIT Award from the NIH
September 13, 2024
https://news.vumc.org/2024/09/11/dooleys-tb-research-receives-merit-award-from-the-nih/
Kelly Dooley, MD, PhD, MPH, Addison B. Scoville Jr. Professor of Medicine and director of the Division of Infectious Diseases at Vanderbilt University Medical Center, has received a MERIT Award (Method to Extend Research in Time Award) from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
VTC to lead a $2.3 million study on subclinical TB
August 5, 2024
The Vanderbilt TB Center will lead a two-year, $2.3 million project funded by CRDF Global, to conduct research on the prevalence and incidence of subclinical tuberculosis(TB) in close contacts and evaluate novel biomarkers and diagnostic tests for subclinical TB. The true prevalence and incidence of subclinical TB in close TB contacts is unclear, and the optimal diagnostic method for subclinical TB is unknown.
NIH Awards UM1 Funding to Establish PReDicTR Consortium
July 31, 2024
Rada Savic, PhD and colleagues Eric Nuermberger, MD (JHU), Kelly Dooley, MD, PhD, MPH (Vanderbilt), and Dirk Schnappinger, PhD (WCM) have been awarded a five-year $30.8M, UM1 cooperative agreement award from NIAID/NIH to establish a consortium of tuberculosis preclinical and clinical experts to research the most effective treatment options for future clinical testing, called the Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium. PReDicTR will establish a mu
RePORT-Brazil Investigators at CROI 2024
March 5, 2024
The 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver was attended by investigators from RePORT-Brazil, including presentations on recent findings and articles. Poster Presentations:Dr. Gustavo Amorim, PhD - "Estimating Optimal Anti-TB Drug Concentrations in a Prospective, Observational Cohort in Brazil"Dr. Felipe Ridolfi, PhD, MD - “Pharmacogenetic Associations With HIV-1 Virologic Suppression Among Patients with TB/HIV in Brazil”
RePORT-Brazil in the Spotlight - CID Article
February 2, 2024
A recently publication in the journal Clinical Infectious Diseases is catching attention. The Xpert® MTB/RIF cycle threshold value predicts M. tuberculosis transmission to close contacts in a Brazilian prospective multicenter cohort was published by the RePORT-Brazil consortium, with authorship being led by the team at the Fundação de Medicina Tropical in Manaus, Amazonas, Brazil.
TB Center welcomes 1st Cohort of RePORT-Brazil Advanced Career Training (ReACT) Fellows
September 20, 2023
The Regional Prospective Observational Research in Tuberculosis - Brazil (RePORT-Brazil) network is pleased to announce its 1st Cohort of Fellows for the RePORT-Brazil Advanced Career Training (ReACT) program.
Strategic Aim 3 of the recently renewed RePORT-Brazil Phase 2 grant (NIH U01AI172064-01), focuses on the development of a fellowship program for the advancement of early-career Brazilian scientists. The program provides funding for pilot projects in TB research, mentorship, and access to data and specimens collected throughout Phase 1 of the project.
RePORT-Brazil in the Spotlight - Discoveries in Medicine
July 28, 2023
Published on July 12, 2023 in Discoveries in Medicine, Research into TB Expands Internationally, is based off of an interview with Timothy R.
TB Center joins 3rd Iteration of RePORT-International Coordinating Center
June 19, 2023
The Vanderbilt TB Center is returning to the leadership team of the RePORT International Coordinating Center, for its 3rd iteration.
VTC Hosts TB/HIV R01 Meeting
May 8, 2023
Vanderbilt Tuberculosis Center recently hosted a meeting of researchers involved in our TB/HIV grant "Predictors of treatment toxicity, failure, and relapse in HIV-related tuberculosis" (NIH R01AI120790-04). The event, which took place on April 26th and 27th, included presentations on the results and findings of each working group, breakout sessions, and discussions on future steps to be taken and larger goals of the research.
VUMC lands Grant to build top-line Biosafety Facility
October 3, 2022
https://news.vumc.org/2022/09/29/vumc-lands-grant-to-build-top-line-biosafety-facility/
Vanderbilt University Medical Center has been awarded a nearly $8 million grant from the National Institutes of Health to construct a state-of-the-art BioSafety Level 3 (BSL3) facility for research involving the COVID-19 virus, anthrax and other dangerous microorganisms. When the renovation of about 3,500 square feet of existing space is completed, the facility will include three BSL3 suites with separate entrances and seven procedure rooms capable of securely containing multiple organisms at the second-highest biosafety level.